The Bulletin
Men's Weekly


.

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

  • Written by PR Newswire

--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023

--Phase I clinical trial will also determine if ASC11 needs to be boosted by ritonavir or not

--In antiviral cellular assays,...

The Bulletin Magazine

Your Reliable Partner for Every Roadside Emergency

Choosing Waterproofing Membranes for Outdoor Spaces: The Essential Attributes You Need

How Modular Content Accelerates Turnaround for Time-Sensitive Campaigns

How Litigation Lawyers in Sydney Can Help Resolve Disputes Efficiently

Revitalising Homes and Offices with Professional Carpet Cleaning Melbourne

Gum Grafting for Receding Gums: Cost, Recovery Time, and What to Expect

Why It’s Convenient to Buy Ceiling Fans Online

Creating Functional and Welcoming Spaces with a Professional Medical Clinic Fitout

10 Thoughtful Gift Ideas That Show You Truly Care

Debt Collection vs. Debt Recovery: What’s the Difference?

CHEAPER RIDES FOR FANS AS 13CABS CUTS FARES FOR FINALS WEEK

Therapeutic Approaches: CBT vs ACT for Depression